Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Though Plasma Multiomics Analysis.

Launched by BEIJING ANZHEN HOSPITAL · Mar 14, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to find out if certain biological markers in the blood can help predict heart problems in people who have had a heart attack, known as acute myocardial infarction (AMI). Specifically, the researchers are looking for signs that can indicate if someone might experience complications with their heart function or other serious heart events after their heart attack. By analyzing these markers, the study aims to understand the underlying biological processes that could lead to these complications.

To take part in this study, participants must be at least 18 years old and have been diagnosed with a heart attack, either STEMI or NSTEMI, confirmed through medical tests. They should be willing to provide consent to participate. However, individuals with previous major surgeries, trauma, or severe kidney issues may not be eligible. If you join the trial, you will help researchers gather valuable information that could improve care for future patients who experience heart attacks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years.
• • 2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
• • 3. Willingness to provide informed consent.
• Exclusion Criteria:
• • 1. Prior surgery or trauma.
• • 2. Renal failure with glomerular filtration \<30 ml/min.